SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., the leader in 3D genomics, today announced the close of its $7 million Series B Preferred Stock financing round. New investors Genetron Health (NASDAQ ...
CARLSBAD, Calif., April 10, 2025--(BUSINESS WIRE)--Arima Genomics, Inc. (Arima), a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve ...
"During my decade at Illumina Ventures, I evaluated countless genomics innovations, yet Arima’s approach stands out for its ability to illuminate aspects of the genome most tests never see," said ...
SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, ...
Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to improve human health and drive discovery in the life sciences, today announced the formation of a clinical ...
The ARIMA statement applies the X-11-ARIMA method to the series specified in the VAR statement. This method uses an ARIMA model estimated from the original data to extend the series one or more years.
Arima is expanding its global presence with the signing of a strategic partnership agreement with Singapore-based market research company, Idstats. This new agreement takes the firm’s self-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results